Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29408804 | 1.00 | MEN1 (0.43) | MEN1USP2MAPTALOX15KMT2A | |
| SCHEMBL10935563 | 0.89 | GAA (0.44) | MEN1USP2MAPTALOX15KMT2A | |
| SCHEMBL10936394 | 0.86 | GAA (0.41) | MEN1USP2MAPTALOX15KMT2A | |
| SCHEMBL10763129 | 0.85 | MEN1 (0.36) | MEN1USP2MAPTALOX15KMT2A | |
| SCHEMBL26696690 | 0.82 | NPC1 (0.50) | MEN1USP2MAPTALOX15KMT2A | |
| SCHEMBL9447545 | 0.80 | GAA (0.38) | MEN1USP2MAPTALOX15KMT2A | |
| SCHEMBL28351619 | 0.78 | MEN1 (0.42) | MEN1USP2MAPTALOX15KMT2A | |
| SCHEMBL10402590 | 0.77 | GAA (0.46) | GAANPC1TSHR | |
| SCHEMBL7102659 | 0.74 | RECQL (0.43) | MEN1USP2MAPTALOX15KMT2A | |
| SCHEMBL29624830 | 0.74 | RECQL (0.43) | MEN1USP2MAPTALOX15KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1207869-A2 | ANTIMYCOTIC DRUG | Novartis AG (CH) | 2002-05-29 | — | — | EP | claimed |
| WO-2001015684-A2 | ANTIMYCOTIC DRUG | NOVARTIS AG (CH) | 2001-03-08 | — | — | WO | claimed |
| EP-1080722-A1 | Antimycotic compositions | Novartis AG (CH) | 2001-03-07 | — | — | EP | claimed |
| US-20240217917-A1 | PHOTOLYTICALLY DEGRADABLE COMPOUNDS AND METHODS | THE UNIVERSITY OF STAVANGER (NO) | 2024-07-04 | — | — | US | disclosed |
| US-20240217917-A1 | PHOTOLYTICALLY DEGRADABLE COMPOUNDS AND METHODS | THE UNIVERSITY OF STAVANGER (NO) | 2024-07-04 | — | — | US | disclosed |
| US-20240217917-A1 | PHOTOLYTICALLY DEGRADABLE COMPOUNDS AND METHODS | THE UNIVERSITY OF STAVANGER (NO) | 2024-07-04 | — | — | US | disclosed |
| EP-4326704-A1 | PHOTOLYTICALLY DEGRADABLE COMPOUNDS AND METHODS | The University of Stavanger (NO) | 2024-02-28 | — | — | EP | disclosed |
| WO-2022223390-A1 | PHOTOLYTICALLY DEGRADABLE COMPOUNDS AND METHODS | THE UNIVERSITY OF STAVANGER (NO) | 2022-10-27 | — | — | WO | disclosed |
| EP-1207869-A2 | ANTIMYCOTIC DRUG | Novartis AG (CH) | 2002-05-29 | — | — | EP | disclosed |
| WO-2001015684-A2 | ANTIMYCOTIC DRUG | NOVARTIS AG (CH) | 2001-03-08 | — | — | WO | disclosed |
| EP-1080722-A1 | Antimycotic compositions | Novartis AG (CH) | 2001-03-07 | — | — | EP | disclosed |
| US-5153224-A | Insecticide or pesticide | CIBA-GEIGY CORPORATION (US) | 1992-10-06 | — | — | US | disclosed |
| US-5107017-A | Insecticides | CIBA-GEIGY CORPORATION (US) | 1992-04-21 | — | — | US | disclosed |
| US-4980506-A | Benzoylphenylureas | CIBA-GEIGY CORPORATION (US) | 1990-12-25 | — | — | US | disclosed |
| EP-0179022-B1 | BENZOYLPHENYL UREAS | CIBA-GEIGY AG (CH) | 1990-11-07 | — | — | EP | disclosed |
| EP-0343110-A1 | Benzoyl phenyl urea compounds | CIBA-GEIGY AG (CH) | 1989-11-23 | — | — | EP | disclosed |
| US-4798837-A | Benzoylphenylureas | CIBA-GEIGY CORPORATION (US) | 1989-01-17 | — | — | US | disclosed |
| EP-0179022-A2 | Benzoylphenyl ureas | CIBA-GEIGY AG (CH) | 1986-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240217917-A1 | PHOTOLYTICALLY DEGRADABLE COMPOUNDS AND METHODS | DDT, DDC, CTRC | MEN1 2480/4885USP2 1204/4885MAPT 2581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.